Request Demo

Last update 27 Feb 2026

Oxymetazoline Hydrochloride

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol

+ [40]

Target

α1A-AR

Action

agonists

Mechanism

α1A-AR agonists(Alpha-1a adrenergic receptor agonists)

Therapeutic Areas

Cardiovascular DiseasesEye DiseasesOtorhinolaryngologic Diseases+ [4]

Active Indication

BlepharoptosisErythemaRosacea+ [4]

Inactive Indication

PresbyopiaSpinal Cord InjuriesUrinary Incontinence

Originator Organization

Schering-Plough Canada, Inc.

Active Organization

Santen SAS

Santen, Inc.Osmotica Pharmaceutical US LLC

+ [7]

Inactive Organization

Actavis, Inc.

Bayer Healthcare LLCAllergan UC

+ [1]

License Organization

Aclaris Therapeutics, Inc.

Allergan plc

Santen Pharmaceutical Co., Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

Canada (31 Dec 1964)

RegulationOrphan Drug (European Union)

Structure/Sequence

Molecular FormulaC16H25ClN2O

InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N

CAS Registry2315-02-8

Clinical Trials associated with Oxymetazoline Hydrochloride

NCT07397325

/ Not yet recruitingPhase 1/2

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia

Start Date16 Mar 2026

Sponsor / Collaborator

Applied Biology, Inc.

[+2]

NCT07390578

/ Not yet recruitingPhase 4IIT

Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study

This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis. Participants will undergo standardized eyelid photography, receive a single dose of either Upneeq or Lumify in randomized order, and have repeat photographs approximately 60 minutes later. They will return for a second visit to receive the alternate medication using the same procedures. Eyelid height measurements will be obtained from coded images by masked graders. Data will be analyzed using paired statistical methods appropriate for a crossover design. Both medications are FDA-approved topical ophthalmic drops, and the study involves minimal risk with anticipated transient ocular irritation as the most common adverse event.

Start Date01 Mar 2026

Sponsor / Collaborator

Duke University

NCT07402330

/ Not yet recruitingEarly Phase 1

Pharmacokinetic Study of DA-020

Start Date16 Feb 2026

Sponsor / Collaborator

Applied Biology, Inc.

[+2]

100 Clinical Results associated with Oxymetazoline Hydrochloride

100 Translational Medicine associated with Oxymetazoline Hydrochloride

100 Patents (Medical) associated with Oxymetazoline Hydrochloride

1,377

Literatures (Medical) associated with Oxymetazoline Hydrochloride

21 Jan 2026·Cardiovascular & hematological agents in medicinal chemistry

Cardiovascular and Cerebrovascular Events Linked to Abuse and Misuse of Sympathomimetic Nasal Decongestants: A Narrative Review of Clinical Evidence

Article

Author: Rashid, Sulthan Al ; Pakkir Maideen, Naina Mohamed

Background::

Sympathomimetic nasal decongestants such as pseudoephedrine, phenylephrine, oxymetazoline, and xylometazoline are commonly used to relieve nasal blockage caused by allergic rhinitis, infections, or sinus inflammation. They work by activating α-adrenergic receptors, which promote vasoconstriction. However, overuse or inappropriate use of these medications has been linked to serious cardiovascular and cerebrovascular side effects.

Objective::

The purpose of this review is to compile the available clinical evidence on the misuse and overuse of sympathomimetic nasal decongestants and their association with detrimental cardiovascular and cerebrovascular outcomes. It examines potential mechanisms, identifies risk factors, highlights diagnostic concerns, and outlines preventive measures.

Methods::

A thorough literature search was conducted using databases such as Medline, Pub- Med, Scopus, Web of Science, and Google Scholar. The selection included case reports, observational studies, pharmacovigilance data, and clinical investigations published in English that evaluated the negative cardiovascular or cerebrovascular effects of sympathomimetic decongestants. Duplicate records were removed.

Results and Discussion::

Although rare, significant events such as myocardial infarction, stroke, hypertensive crises, and vasospasm have been documented with both oral and intranasal sympathomimetics, particularly when used excessively or in combination with other medications. Strong vasoconstriction, endothelial dysfunction, and elevated sympathetic activity are the primary mechanisms underlying these adverse effects. Nonspecific symptoms and underreporting of OTC drug use can delay diagnosis. Numerous reports suggest potentially serious or fatal outcomes, and most clinical evidence comes from case reports rather than high-level studies.

Conclusion::

Sympathomimetic nasal decongestants are generally safe when used as directed. However, excessive or inappropriate use may lead to potentially fatal cerebrovascular and cardiovascular events. Healthcare professionals should thoroughly review patients’ medication histories and provide clear instructions on proper use. Educating patients on the correct administration of sympathomimetic nasal decongestants and encouraging safer alternatives such as intranasal corticosteroids or saline sprays, when appropriate, is essential. Preventive measures, regulatory oversight, and interprofessional collaboration are crucial to ensuring safe use and reducing adverse outcomes.

03 Jan 2026·Cureus Journal of Medical Science

Management of Complications Following Botulinum Toxin Facial Injections: A Narrative Review

Review

Author: Camões-Barbosa, Alexandre ; Freixo, Sara

Botulinum toxin (BoNT) is widely used in the management of neurological disorders and in aesthetic medicine. Although generally safe, facial injections may be associated with complications with relevant functional or aesthetic impact. This narrative review aimed to summarize reported facial complications following BoNT injections and to describe available management strategies. A PubMed search up to November 2025 identified 239 articles; after screening and full-text review, 20 studies met the inclusion criteria. Data were synthesized narratively due to the heterogeneity of study designs. Upper eyelid ptosis was the most frequently reported clinically significant complication and was mainly managed with topical alpha-adrenergic agonists. Diplopia was rare but functionally disabling and was treated conservatively with occlusion or prisms or with targeted extraocular BoNT injection in selected cases. Ocular surface changes, facial asymmetry, perioral dysfunction, local reactions, and headache were generally mild and self-limited. Systemic adverse events were uncommon but occasionally required hospital evaluation. Overall, management strategies were predominantly conservative and supported by low-level evidence. Facial BoNT injections are generally safe, but clinically relevant complications can occur. Management is largely conservative, apraclonidine 0.5% is most commonly used for toxin-induced ptosis, and oxymetazoline 0.1% (FDA-approved for acquired blepharoptosis) is an additional option; other events are treated symptomatically. Overall, evidence is limited, supporting the need for prospective studies and standardized management pathways.

02 Jan 2026·JOURNAL OF ADDICTIVE DISEASES

Severe nasal spray oxymetazoline use disorder – a case report

Article

Author: Podwojniak, Alicia Collette ; Pullinger, Benjamin ; Jermyn, Richard ; Chen, Kathy ; Garcia, Andrea ; Jabon, Jaimy D.

Oxymetazoline hydrochloride 0.05% is a lipophilic sympathomimetic nasal decongestant spray available over the counter (OTC) and commonly used for allergic and chronic rhinitis. A well-known side effect of these nasal sprays is rebound congestion termed rhinitis medicamentosa (RM), but there is little literature attesting to the relationship between RM and substance use disorder. This is a case report of severe nasal spray oxymetazoline use disorder per DSM-5 criteria discovered incidentally in a 44-year-old patient receiving care at a residential addiction treatment center for long-standing polysubstance use and bipolar disorders. The patient began using oxymetazoline in 2003 for allergic rhinitis and developed rhinitis medicamentosa that progressed to an oxymetazoline use disorder. Despite medical and clinical interventions, cravings and urges prevented her from stopping the nasal spray. We discuss the pharmacological properties of oxymetazoline, the behavioral aspects of its intranasal administration, and the drug-induced rebound congestion that may contribute to its misuse. To our knowledge, this is the first reported case of oxymetazoline use disorder lasting 20 years.

News (Medical) associated with Oxymetazoline Hydrochloride

08 Jan 2026

·www.prnewswire.com

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

BRIDGEWATER, N.J., Jan. 8, 2026 /PRNewswire/ -- RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq® is the first and only FDA-approved prescription eye drop for acquired blepharoptosis (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. "UPNEEQ® was developed to provide patients with a meaningful, non-invasive alternative to eyelid surgery," said Lori Deo, Chief Executive Officer of RVL Pharmaceuticals. "Our partnership with Santen allows us to extend this innovation to patients in Japan. Together, we are addressing a significant unmet need and helping advance new standards of care for acquired blepharoptosis." Approval in Japan was supported by a Phase 3, placebo-controlled, randomized, double-masked study conducted in Japan, the efficacy and safety of once-daily administration of the product were evaluated in patients with acquired blepharoptosis. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil)* at Day 14 after the start of treatment—in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward weakening of the eyelid-lifting effect or rebound effect was observed. * In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. About Upneeq® in the United States Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults. The product was approved in the US by the FDA in July 2020. Important Safety Information Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse. Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren's syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse. UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ. Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used. The most common adverse reactions with UPNEEQ (occurring in 1–5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full U.S. Prescribing Information for UPNEEQ. About RVL Pharmaceuticals RVL Pharmaceuticals, Inc operates a digitally enabled, vertically integrated commercial platform spanning product acquisition through order fulfillment, meeting consumers and healthcare providers where they are. Its lead product, Upneeq®, provides a non-surgical eyelift for adults with acquired ptosis. Upneeq® activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals, Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800. For more information, please visit . About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" – Exploring the secrets and mechanisms of nature in order to contribute to people's health – Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit Media Contact: Lippe Taylor [email protected] SOURCE RVL Pharmaceuticals, Inc 21% more press release views with Request a Demo

Phase 3Clinical ResultLicense out/inDrug Approval

20 Feb 2025

·www.pharmaindustrial-india.com

Cosette Pharmaceuticals Acquires Mayne Pharma to Expand Globally

Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited at AUD 7.40/share for a total consideration of approximately USD 430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recommended that its shareholders vote in favor of the transaction. The transaction is expected to close in the second quarter of 2025. “This acquisition marks a transformational step for Cosette, adding patented, high-growth products to solidify our leadership in women’s health in the US and expanding our reach globally. By combining Cosette’s strong portfolio with Mayne Pharma’s proven commercial expertise, the combined company will be well positioned to further invest in innovation, portfolio expansion and better serve our patients. We look forward to a timely closing and welcoming Mayne Pharma to the Cosette family,” said Apurva Saraf, President and CEO of Cosette Pharma. “Joining the Cosette team amplifies our shared mission to improve lives through innovative and accessible Women’s health and dermatology medicines. This transaction represents a unique opportunity for our employees, customers, and patients. Together, we will extend the reach of important therapies, drive innovation, and improve patient access,” said Shawn Patrick O’Brien, CEO, Mayne Pharma. The combination will create a leading women’s health and dermatology focused pharmaceuticals company in the U.S. with an established presence in international markets, utilizing the strengths of two industry players to drive innovation and expand access to women’s health therapies. Cosette will utilize its market-leading commercial and operational capabilities, backed by its 350+ strong team and a leading portfolio of women’s health and dermatology products alongside Mayne Pharma’s complementary strength in these specialty areas. Mayne Pharma is backed by a 480+ strong team, including highly effective and successful sales and marketing teams in both specialties. The combined company will have two state-of-the-art FDA -approved manufacturing sites – one each in Lincolnton, North Carolina and Salisbury, South Australia – to service patients globally. Upon close, Cosette will market 12 patent-protected products focused on women’s health and dermatology, including leading brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®, and several programs in clinical development.

Acquisition

21 Nov 2024

·www.businesswire.com

Nasal Sprays Help Alleviate Nasal Congestion

AMERICAN FORK, Utah--( BUSINESS WIRE )--Today, Nathan Jones, CEO of Xlear Inc., a consumer hygiene products company, released this statement regarding the FDA’s proposal to remove popular over-the-counter decongestants, which contain the drug phenylephrine, from the market: “With the FDA concluding that this common decongestant isn’t effective, as we enter cold and flu season, and as families prepare to celebrate the holidays, many Americans need a new answer for the discomfort of sinus congestion,” Jones noted. “For people looking for help, the U.S. Centers for Disease Control (CDC) Guidance, ‘Relief for Symptoms of Colds and Coughs’, ‘instructions’ say to ‘use saline nasal spray to relieve congestion.’ i Similarly, CDC’s ‘Sinus Infection Basics’ say ‘How to Feel Better’ ‘use a . . . saline nasal spray,’” ii he pointed out. “You experience congestion because there is an irritant or pathogen in your upper airway that your body is trying to trap and wash away—your runny nose is your body flushing it out. Saline-based nasal sprays can help speed up that flushing, reduce pathogen load, and make it more effective. It’s commonsense: The faster the bad stuff is gone, the faster you feel better,” Jones added. “For congestion caused by pathogens—like colds and flus—people can enhance that effect by using a nasal spray that contains xylitol. A series of studies show xylitol (a natural sugar) deactivates and/or blocks the adhesion of many types of viruses and bacteria, to your airway cells,” iii Jones continued. Adhesion is the process by which a pathogen attaches to your tissue to initiate infection. Using a nasal spray with xylitol helps block adhesion of these pathogens. For example, a Randomized Controlled (clinical) Trial published in 2022, determined that a saline-nasal spray containing xylitol and other ingredients reduced the rate of COVID-19 infections by 62 percent above placebo. iv “Using a basic saline would be comparable to rinsing your hands with water; using a nasal spray with xylitol, like Xlear , would be comparable to washing your hands with soap. Expect more from your nasal hygiene products. Make sure they have xylitol so you can better and faster clean out the bad stuff while alleviating the congestion,” Jones added. Xlear nasal spray is a saline-based nasal spray containing xylitol. Xlear 12 Hour Nasal Decongestant is a saline-based nasal spray containing xylitol and the decongestant Oxymetazoline HCL. For more information on Xlear please visit www.xlear.com . ____________________________ i https://www.cdc.gov/antibiotic-use/media/pdfs/HCP-Relief-Colds-Cough-85by11-P.pdf ii https://www.cdc.gov/sinus-infection/about/index.html iii For example: T Kontiokari, M Uhari, M Koskela, Antiadhesive effects of xylitol on otopathogenic bacteria., Journal of Antimicrobial Chemotherapy , Volume 41, Issue 5, May 1998, Pages 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext - google_vignette ; Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy , 41 (5), 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext&login=false ; Jung, Kie Hoon. (2021). Antiviral Efficacy Against Virus Infections in Human-Derived Tracheal/Bronchial Epithelial Cells. Utah State University, https://xlrtmp.com/wp-content/uploads/2023/05/Antiviral-efficacy_USU2021.pdf ; Vega, J. C., et al., (2020). Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. BioRxiv , https://professionals.xlear.com/portfolio/anti-adherence-of-viruses/ ; Ruiz, V., Rodríguez-Cerrato, V., Huelves, L. et al. Adherence of Streptococcus pneumoniae to Polystyrene Plates and Epithelial Cells and the Antiadhesive Potential of Albumin and Xylitol. Pediatr Res 69, 23–27, https://www.nature.com/articles/pr920116 - citeas . iv Damian Balmforth, et al., Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial., Journal of Clinical Virology, 155; 2022, https://www.sciencedirect.com/science/article/pii/S1386653222001809 .

100 Deals associated with Oxymetazoline Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01022	Oxymetazoline Hydrochloride	R01AA05 S01GA04 R01AB07	DB00935

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Blepharoptosis	United States	RVL Pharmaceuticals, Inc.	08 Jul 2020
Erythema	United States	Mayne Pharma Ltd.	18 Jan 2017
Hyperemia	Japan	Sato Pharmaceutical Co., Ltd.	01 Aug 2007
Nasal Obstruction	China	Changzhou Yabang Pharmaceutical Co., Ltd.	01 Jan 1992
Rosacea	United States	Bayer Healthcare LLC	30 May 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Blepharophimosis	Phase 3	Czechia	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	France	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Germany	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Hungary	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Italy	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Netherlands	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Poland	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Spain	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	United Kingdom	Santen SAS	30 Dec 2024
Fecal Incontinence	Phase 2	Hungary	RDD Pharma Ltd.	01 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05715346 (CTgov)	Phase 1/2	Blepharoptosis	33	LEV102 2.0% (LEV102 Topical Gel, 2.0%)	ezdjebwreq = ffmrxetrqj dnfdbarbpn (qlaajuuzlh, qvoatxikko - sudlpdipzn) View more	-	13 Nov 2024
				LEV102 1.0% (LEV102 Topical Gel, 1.0%)	ezdjebwreq = djogbcnzcm dnfdbarbpn (qlaajuuzlh, cmfhktlnuh - czkthoprgo) View more
NCT04831047 (CTgov)	Phase 4	Eye Redness \| Conjunctivitis \| Blepharoptosis	114	Oxymetazoline hydrochloride 0.1% ophthalmic solution (Upneeq Group)	ouqhkmnrup(jyqwhoosfh) = rrzxwgrcmv hwqduqcyvs (smsfmosjzn, 1.1) View more	-	24 Apr 2023
				Placebo (Control Group)	ouqhkmnrup(jyqwhoosfh) = eluksyxjif hwqduqcyvs (smsfmosjzn, 0.8) View more
NCT04831047 (Pubmed \| J Plast Reconstr Aesthet Surg)	Not Applicable	Eye Redness \| Conjunctivitis \| Blepharoptosis	114	Topical oxymetazoline 0.1%	qvodhphdoo(psmuzqoaxf) = luskdpwrpz efajvwgbvq (wdheazbvbj )	Positive	09 Feb 2023
NCT04153188 (CTgov)	Phase 4	Rosacea	34	The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream)	qzghewycga(wdhjysifym) = yfyawmuuhm skqjbsdnam (oqlklqksmf, 1.0) View more	-	18 Mar 2022
				Oxymetazoline HCL 1% Cream (Oxymetazoline HCL 1% Cream)	qzghewycga(wdhjysifym) = htzfpcihmk skqjbsdnam (oqlklqksmf, 1.0) View more
NCT01848041 (CTgov)	Phase 1/2	Blepharoptosis	46	RVL-1201 (RVL-1201 Once Daily)	swzkbtyior(kzmrinuuli) = kzrmczwsxo rifoejglhz (ekvrzfqcah, 5.07) View more	-	22 Jul 2021
				RVL-1201 (RVL-1201 Twice Daily)	swzkbtyior(kzmrinuuli) = ufwffjxykl rifoejglhz (ekvrzfqcah, 4.64) View more
NCT03954444 (CTgov)	Phase 3	Rosacea	1,105	Oxymetazoline Hydrochloride (Oxymetazoline Hydrochloride Cream, 1%)	jalesmutnf: Mean Difference (Net) = 2.7 (90% CI, -2.6 to 8.0)	-	23 Jun 2021
				Rhofade Cream, 1% (RHOFADE Cream, 1%)
NCT03228914 (CTgov)	Phase 4	Hemorrhage \| Nasal Polyps	20	Oxymetazoline (Oxymetazoline)	rhcqvmzoih(vjndkigvhq) = ahrsixcvbq kyyqebapye (avafblttnb, 0.19) View more	-	13 Jan 2021
				Epinephrine (Epinephrine)	rhcqvmzoih(vjndkigvhq) = vuczzvqzjq kyyqebapye (avafblttnb, 0.15) View more
NCT03352323 (CTgov)	Phase 3	Rosacea \| Erythema	50	Oxymetazoline	eisenttber = wtbulmlznp mrqgnrzetu (rqzqilchmk, hivqrmzniy - paboyqmcnw) View more	-	05 Jan 2021
NCT02780115 (CTgov)	Phase 2	Presbyopia	151	AGN-190584 Vehicle	wwkkrljbvy(utlrekoxzb) = oxilvdoaha vglbmqsmqn (ggirrueyaq, 1.03) View more	-	22 Dec 2020
NCT02595528 \| NCT02780115 (PA039, AAO2020)	Phase 2	Presbyopia	-	Pilocarpine 1.0%/Oxymetazoline 0.05%	pjfqsfejpv(jjspglumwi) = iwipccpbkv jqaynrpevh (wwjdpcysri )	Positive	13 Nov 2020
				Pilocarpine 1.5%/Oxymetazoline 0.125%	pjfqsfejpv(jjspglumwi) = jkqceneavs jqaynrpevh (wwjdpcysri )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis